Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand" is generating significant coverage in the Business category, with 8 articles from 8 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, WSJ, Eli Lilly and Barchart.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 18d ago.
Quick answers
Why is "Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mo" trending?
Because 8 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales Yahoo Finance · 19d ago
- Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound WSJ · 19d ago
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio Eli Lilly · 19d ago
- Ahead of Eli Lilly Earnings, Here's What Barchart Data Says Comes Next for LLY Stock Barchart.com · 19d ago
- Eli Lilly Stock Jumps as Monster Earnings Powered by Mounjaro and Zepbound Barron's · 19d ago
- Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges Reuters · 19d ago
- Lilly Raises Sales Guidance, Widening Its Lead in Obesity Market Bloomberg · 19d ago
- Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand CNBC · 19d ago
Topics
Related trends
Ozempic and Mounjaro may have a surprising effect on your brain
Coverage from five outlets reports that Ozempic and Mounjaro may affect memory and brain function, with evidence described as mixed.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.